Trodelvy Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The trodelvy market research report is one of a series of new reports that provides trodelvy market statistics, including trodelvy industry global market size, regional shares, competitors with a trodelvy market share, detailed trodelvy market segments, market trends, and opportunities, and any further data you may need to thrive in the Trodelvy industry. This trodelvy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the expanding pipeline of ADC therapies, growing focus on combination therapies, increasing healthcare infrastructure, focus on patient-centric cancer care, supportive regulatory landscape. Major trends in the forecast period include clinical advancements, advancements in targeted cancer therapies, advancements in immuno-oncology, collaboration between biotech and pharmaceutical companies, development of novel treatment modalities.

The increasing incidence of breast cancer is expected to drive the growth of the trodelvy market. Breast cancer is a type of cancer where malignant cells develop in the breast tissue. It is among the most common cancers globally, affecting both women and, to a lesser extent, men. The rise in breast cancer cases can be attributed to factors such as genetic predisposition, lifestyle changes, and greater awareness, which have led to more investments in advanced treatments and healthcare infrastructure worldwide. Trodelvy plays a crucial role for breast cancer patients, offering targeted treatment options for advanced or metastatic cases, thereby improving survival rates and addressing the growing healthcare demands related to the high incidence of the disease. According to the American Cancer Society, around 313,510 new cases of breast cancer were diagnosed in 2024, a slight increase from 300,590 cases in 2023. This growing incidence of breast cancer is contributing to the expansion of the trodelvy market.

A key trend in the trodelvy market is the expansion of its treatment indications, allowing the drug to offer targeted therapies to a broader range of patients, ultimately improving survival outcomes and quality of life. This approach addresses unmet medical needs across various oncology indications, enhancing the drug’s clinical and commercial potential. For example, in February 2023, Gilead Sciences received expanded approval from the United States for Trodelvy to treat HR-positive and HER2-negative metastatic breast cancer, greatly broadening the market and increasing its potential patient base. This expansion represents a significant strategic move for Trodelvy, enabling it to compete more effectively in the larger breast cancer treatment landscape.

In August 2022, Gilead Sciences acquired the development and commercialization rights for Trodelvy (sacituzumab govitecan) in several Asian markets from Everest Medicines for $280 million. This acquisition allows Gilead to streamline its operations in Asia and use its resources to further develop Trodelvy in these regions. Everest Medicines, a biotech company based in China, had previously been responsible for developing and commercializing the drug in specific Asian markets.

The key company operating in the trodelvy market is Gilead Sciences Inc.

North America was the largest region in the trodelvy market in 2024. The regions covered in trodelvy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the trodelvy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Trodelvy is an antibody-drug conjugate (ADC) that combines a monoclonal antibody with a chemotherapy agent. The monoclonal antibody targets Trop-2, a protein frequently overexpressed in certain cancer cells, allowing the chemotherapy to be delivered directly to these cancerous cells.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for Trodelvy include metastatic triple-negative breast cancer (mTNBC), HR+ or HER2-negative breast cancer, and metastatic urothelial cancer. mTNBC is a subtype of breast cancer characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). Trodelvy is distributed through various channels, including hospitals, clinics, retail, and specialty pharmacies, and is used by a range of patients, including both adults and the elderly.

The trodelvy market consists of sales of companion diagnostic tests and antibody-drug conjugates, and adjunctive therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.